Regarding therapeutic application targeting the FAM83H-SCRIB pathway, the knock-down of FAM83H and/or SCRIB inhibited the growth of various human cancer cells, such as hepatocellular carcinoma [3], gastric carcinoma [7], ovarian carcinoma [24], and osteosarcoma [6]. The gene discussed is SCRIB; the disease is gastric carcinoma.